Jump to content
  • History of the RRDi


    There was a post at a Yahoo group in  November 23, 2002 that started the idea of making a non profit organization for rosacea sufferers to collaborate together. 

    The Rosacea Research & Development Institute began as an idea by the founder, Brady Barrows, on November 23, 2002 when he founded the following yahoo group:

    health.groups.yahoo.com/group/international-rosacea-society

    The above yahoo group was changed on July 24, 2004 to:

    health.groups.yahoo.com/group/irosacea

    And then later changed on February 14, 2005 to this yahoo group:

    health.groups.yahoo.com/group/rosacea-research

    The above yahoo group was deleted June 7, 2006 since the private forum for corporate members began in April/May 2006. Since then, Yahoo Groups has been removed from the internet. 

    A need for a non-profit organization that heard the voice of rosaceans suffering from this disease was seen early on and discussion continues to this day. Upon moving to Hawaii the founder discovered that forming a non-profit organization in this state would be simpler than in other states and applied for approval as a non-profit corporation. A Charter was set up. The non profit recognition was approved on June 7, 2004 by the State of Hawaii and after a lengthy period, tax-exempt approval as a 501 (c) (3) non profit organization was obtained by the IRS in January 2006 and recognition was effective back to June 7, 2004. This process took over a year and a half. More details of all this are written in the article Why Form Another Non Profit Organization For Rosacea?

    The Board of Directors were chosen by the corporation members and the officers were appointed in January 2005. More board members were added in 2006 and later.

    The web site is constantly being improved by volunteers. Volunteers are seeking funding and you can join us to seek corporate donations, seek grants, or find the best minds to join the RRDi MAC, the only medical advisory committee volunteering to find a cure for rosacea, listen to corporate RRDi members' concerns and advise the board of directors on the direction the RRDi should go. Several private member forums were experimented which have not proven popular. For a number of years the RRDi recommended Warren Stuart's www.rosaceagroup.org as the public forum and volunteers have made the private forum for corporate members on the irosacea.org web site. To use the public forum you must join the RRDi. This public corporate member forum is where decisions are discussed. The public forum can be found at this url:

    http://irosacea.org/forums

    Steve Andreessen spent many volunteer hours on not only the above IPB forum (now called Invision Community)  but also our web site. Warren Stuart has also spent many hours volunteering on the web site as well. Under Warren's direction we purchased the Invision Power Services forum (now called Invision Community). Sadly, Warren Stuart passed away. David Pascoe took over Warren's Rosacea Forum. The focus of the RRDi for years has been to gather together the best minds on rosacea into the RRDi Medical Advisory Committee, gathering volunteers to raise public awareness of the RRDi in the Public Relations Committee and to increase RRDi membership, and finally to increase funding through volunteer efforts in the Funding Committee by volunteers. You can see the results of all this volunteer effort and you can become part of it by joining with just an email address. You may want to read the Message from the Founder and our post about Anonymity, Transparency and Posting before joining.

    The RRDi has been affiliated with sponsoring Tapatalk since some users prefer using Tapatalk on mobile devices. In 2019 we have sponsored a private Tapatalk Rosaceans Forum



  • Posts

    • Arch Dermatol Res. 2021 Sep 14. doi: 10.1007/s00403-021-02277-0. Online ahead of print. ABSTRACT Botulinum toxin A (BTX-A) injections have become the most popular noninvasive cosmetic procedures performed worldwide. With growing interest, investigators continue to uncover an expanding array of aesthetic indications for BTX-A. Botulinum toxin A has been used off-label in the management of masseter hypertrophy for facial slimming, platysmal bands, nasal 'bunny' lines, perioral rhytides, gummy smile and scars, to name a few. Interestingly, the injection of multiple microdroplets of dilute BTX-A into the dermis, sometimes referred to as 'microbotox', has been investigated as a tool for facial rejuvenation. A handful of prospective studies and case series have demonstrated the benefit of BTX-A in the treatment of facial erythema and improving skin texture. The aim of this review is to summarize and appraise currently available data on the role of BTX-A in treating facial erythema and skin quality, with a special focus on potential pathophysiologic mechanisms. PMID:34519860 | DOI:10.1007/s00403-021-02277-0 {url} = URL to article
    • Dermatology. 2021 Sep 7:1-6. doi: 10.1159/000518220. Online ahead of print. ABSTRACT BACKGROUND: The prevalence and impact of pruritus, pain, and other sensory symptoms in skin diseases are poorly known. OBJECTIVE: To assess the frequency of these symptoms with dermatoses and their association with depression using data from the "Objectifs Peau" survey. METHODS: A representative sample of 20,012 French individuals was created using the usual quota method. RESULTS: When patients suffered from both pruritus and skin pain, they had a higher relative risk of psychological suffering (2.9) than those who suffered only from pruritus (1.4) or skin pain (1.2). Pruritus was reported in 48.55% of patients with acne, 43.24% with mycoses, 44.35% with warts, and 36.51% with rosacea. For skin pain, the results were 11.22%, 27.59%, and 16.13% for atopic dermatitis, acne, and warts, respectively. Other unpleasant sensations, such as tingling or burning, were also frequently reported. CONCLUSION: Pruritus, pain, or other sensory symptoms were found to be common not only in classic pruritic skin diseases but also in acne, rosacea, or warts. The association of pruritus and pain dramatically increased psychological suffering. These symptoms must be systematically searched for in patients, especially since new therapeutic possibilities are emerging for the symptomatic treatment of pruritus. PMID:34515100 | DOI:10.1159/000518220 {url} = URL to article
    • Arch Dermatol Res. 2021 Sep 12. doi: 10.1007/s00403-021-02279-y. Online ahead of print. ABSTRACT Rosacea is a chronic inflammatory skin condition that is associated with multiple systemic comorbidities, with the strongest evidence linking rosacea to hypertension, dyslipidemia, inflammatory bowel disease, and anxiety and depression. To assess dermatologists' awareness of and screening practices for rosacea comorbidities, we developed a survey that was distributed to attendings and residents across four academic dermatology departments in Massachusetts. A total of 73 dermatologists with varying experience participated in the study. Findings demonstrated significant knowledge and practice gaps among academic dermatologists in managing systemic comorbidities in rosacea. In addition, dermatologists' awareness of rosacea comorbidities was negatively correlated with number of years out of residency training, highlighting the need to address this knowledge gap through increased continuing medical education. Importantly, we observed a low screening frequency despite a high awareness of the association between rosacea and ocular comorbidities, suggesting that additional financial, institutional, or practice barriers likely contribute to the low screening rate. PMID:34510277 | DOI:10.1007/s00403-021-02279-y {url} = URL to article
    • J Cosmet Dermatol. 2021 Sep 12. doi: 10.1111/jocd.14454. Online ahead of print. NO ABSTRACT PMID:34510704 | DOI:10.1111/jocd.14454 {url} = URL to article
    • Vestn Otorinolaringol. 2021;86(4):95-98. doi: 10.17116/otorino20218604195. ABSTRACT One of the frequent causes of a significant increase in the external nose, forming a persistent deformity of the face, as well as leading to a non-standard clinical picture is rhinophyma disease. The article considers some historical data, epidemiology, peculiarities of pathogenesis, as well as the basics of surgical treatment tactics along with possible preventive measures against rhinophyma. At present, the treatment of this pathology presents great difficulties. Despite the many surgical methods, rhinophyma is poorly treatable, often relapses and leaves no less noticeable disfigurement of the face in the postoperative period. In this regard, there is a constant search for new surgical methods, which has not only medical but also important social significance. PMID:34499455 | DOI:10.17116/otorino20218604195 {url} = URL to article MORE INFORMATION ON PHENOTYPE 5
×
×
  • Create New...